Info@ThinkPinkRocks.com

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics’ investigational cancer immunotherapy CAVATAK, with MSD’s KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

View original post here:
Viralytics enters into clinical trial collaboration agreement with MSD

Share

Leave a Reply